FIGURE 6.

Effect of MEDI1814 on CSF (A), plasma NfL (B), and p‐tau217 (C) levels after administration of three monthly IV doses to patients with AD. Compared to baseline, CSF NfL levels were reduced after three monthly IV doses of MEDI1814 1800 mg compared to a median increase in placebo‐treated patients (A). Similarly, plasma NfL levels were reduced after three monthly IV doses of MEDI1814 1800 mg compared to a median increase in placebo‐treated patients (B). Data are mean ± standard error. Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; IV, intravenous; NfL, neurofilament light chain; p‐tau, phosphorylated tau.